Publication: Characterization and vaccine potential of Fasciola gigantica saposin-like protein 1 (SAP-1)
1
Issued Date
2017-01-15
Resource Type
ISSN
18732550
03044017
03044017
Other identifier(s)
2-s2.0-85006726069
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Veterinary Parasitology. Vol.233, (2017), 115-122
Suggested Citation
Pornanan Kueakhai, Narin Changklungmoa, Pinkamon Waseewiwat, Thanaporn Thanasinpaiboon, Werachon Cheukamud, Pannigan Chaichanasak, Prasert Sobhon Characterization and vaccine potential of Fasciola gigantica saposin-like protein 1 (SAP-1). Veterinary Parasitology. Vol.233, (2017), 115-122. doi:10.1016/j.vetpar.2016.12.009 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/42856
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Characterization and vaccine potential of Fasciola gigantica saposin-like protein 1 (SAP-1)
Other Contributor(s)
Abstract
© 2016 Elsevier B.V. The recombinant Fasciola gigantica Saposin-like protien-1 (rFgSAP-1) was cloned by polymerase chain reaction (PCR) from NEJ cDNA, expressed in Escherichia coli BL21 (DE3) and used for production of a polyclonal antibody in rabbits (anti-rFgSAP-1). By immunoblotting and immunohistochemistry, rabbit IgG anti-rFgSAP-1 reacted with rFgSAP-1 at a molecular weight 12 kDa, but not with rFgSAP-2. The rFgSAP-1 reacted with antisera from mouse infected with F. gigantica metacercariae collected at 2, 4, and 6 weeks after infection. The FgSAP-1 protein was expressed at a high level in the caecal epithelium of metacercariae and NEJs. The vaccination was performed in Imprinting Control Region (ICR) mice (n = 10) by subcutaneous injection with 50 μg of rFgSAP-1 combined with Alum adjuvant. Two weeks after the second boost, mice were infected with 15 metacercariae per mouse by the oral route. The percents protection of rFgSAP-1 vaccine were estimated to be 73.2% and 74.3% when compared with non vaccinated-infected and adjuvant-infected controls, respectively. The levels of IgG1 and IgG2a specific to rFgSAP-1 in the immune sera, which are indicative of Th2 and Th1 immune responses, were inversely and significantly correlated with the numbers of worm recoveries. The rFgSAP-1-vaccinated mice showed significantly reduced levels of aspartate aminotransferase (AST) and alanine aminotransferase (ALT), and liver damage. These indicated that rFgSAP-1 has strong potential as a vaccine candidate against F. gigantica, whose efficacy will be studied further in large economic animals including cattle, sheep, and goat.